Introduction
The role of cytokines in the initiation and control of an immune response is now well established, as is the recognition that the type of immune response obtained is critical in determining the effectiveness of the response (1) (2) (3) (4) . In murine leishmaniasis, the associated immune response may be predominantly mediated by T h 1 cells that secrete pro-inflammatory cytokines (type 1 cytokines, e.g. IFN-γ and IL-12) or by T h 2 cells that secrete anti-inflammatory cytokines (type 2 cytokines, e.g. IL-4 and IL-10) (1-3). In the former case, the T h 1 response is effective in controlling the disease, while in the latter case, the T h 2 response is not (1) (2) (3) . This relationship obviously is dependent on the nature of the pathological state. In leishmaniasis, a T h 1 response is associated with decreased pathology (1-3), while in an autoimmune disease, e.g. one that involves the destruction of pancreatic β cells, a T h 1 response is associated by enhanced pathology (4) . Of special relevance to the present study, given the above, is the fact that the type of response obtained can be skewed one way or the other by the timely injection of an appropriate cytokine or anti-cytokine. The control of tumor growth undoubtedly involves a spectrum of effector functions which are both Correspondence to: R. L. Coffman
Transmitting editor: P. C. Doherty Received 14 October 1997, accepted 25 February 1998 immune and non-immune in nature. How these effector functions are controlled by cytokines is not yet fully understood. The present study was undertaken to test the effects of the anti-inflammatory cytokines IL-4 and IL-10 on the rejection response of a syngeneic immunogenic tumor. Both IL-4 and IL-10 have been shown to have anti-tumor effects in mouse models with highly aggressive transplantable tumors, but their effects on the immune response to less aggressive, more immunogenic tumors have not been determined. These cytokines were administered systemically after the tumor was established rather than being expressed by the tumor cells themselves, as was done in most other studies, e.g. (5) (6) (7) (8) . The indicator tumor cell line employed was the DBA/2 mastocytoma P815 genetically altered to express B7.1 (CD80); this tumor cell line was carried on B6D2F1 (C57Bl/6ϫDBA/2)F 1 female mice. The rationale for this selection, i.e. P815.B7 on B6D2F1 mice, was based on the need of a tumor that was immunogenic but which, if the rejection process were compromise, would grow aggressively revealing the effect of the cytokine treatment.
Methods

Mice
Female B6D2F1, 6 weeks of age, were purchased from Simonsen Laboratories (Gilroy, CA). The mice were kept in the DNAX animal facility and used when 8 weeks old. C.B-17 scid mice were bred at DNAX (Palo Alto, CA).
Cell culture mediums and reagents
Splenic single-cell suspensions were prepared in HBSS (Sigma, St Louis, MO) containing 1% FCS, penicillin (100 U/ ml), streptomycin (100 mg/ml) and HEPES buffer (10 mM). Splenic cells were cultured in RPMI 1640 (JR Scientific, Woodland, CA) with 10% FCS (JR Scientific), 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin and 10 mM HEPES. RPMI 1640 thus supplemented was designated RPMIϩ.
Tumor cells were washed with Dulbecco's PBS without Ca 2ϩ or Mg 2ϩ and at pH 7.4 (Sigma, St Louis, MO); tumor cells were also suspended in PBS for inoculation. Splenic erythrocytes were lysed using pyrogen-free, deionized distilled water (Sigma) as follows: spleen cell pellets were loosen, 5 ml of distilled water was added and mixed, and immediately made isotonic by the addition of an equal volume of 2-fold concentrated PBS.
Tumors
The DBA/2 mastocytoma P815 and two transfected sublines of P815 (i.e. P815.B7 and P815.NeoR) were used. P815 was obtained from the ATCC (Rockville, MD). P815.B7 (MC202A5) (B7 ϭ B7-1 or CD80) and P815.NeoR (MC506/Q) tumor cells were provided by Dr L. Lanier (DNAX) (9) .
Tumor cell maintenance and injection
Transfected tumor cell lines were maintained and expanded in RPMIϩ medium containing 0.7 mg of G418/ml (Gibco, Grand Island, NY). The cells were maintained in log phase growth for 2 or 3 days prior to inoculation by daily subculturing; the density was not allowed to exceed 5ϫ10 5 cells/ml. The cells were harvested by centrifugation, washed twice and resuspended in PBS to the desired concentration; tumor cells were inoculated intradermally (i.d.) in the abdominal region on day 0 in a volume of 0.02 ml. The size of the tumors were measured every third or fourth day. Two measurements of the diameter of the tumor were made at right angles to each other in millimeters, and the average diameter was calculated and plotted against time in days.
Cytokines
Mouse rIL-4 and rIL-10 treatment was started on day 7. Mouse rIL-4 and rIL-10 were provided by Dr S. Menon (DNAX). Several preparations of each were used. The characteristics of a typical mouse rIL-4 preparation and a mouse rIL-10 preparation were as follows: rIL-4: 1.42 mg/ml with~10 8 units of biological activity/mg; rIL-10: 1.30 mg of protein/ml with 6.5ϫ10 7 RU (sp. act.)/ml. All preparations had Ͻ2.0 EU/mg protein. Cytokines were diluted in pyrogen-free PBS to a concentration that delivered the desired amount of cytokine in a volume of 0.2 ml. In the case of IL-4, the cytokine was given alone (IL-4 alone) or as a soluble immune complex (IL-4 CPX). IL-4 CPX was prepared by mixing equal molar concentrations of IL-4 and the monoclonal anti-IL-4 antibody 11B11 (ATCC HB 188) (10). Cytokine solutions were injected i.p. Control mice were given just PBS.
Antibodies
The following mAb were employed in this study: rat IgG2b anti-CD4 (GK 1.5; ATCC TIB 207), rat IgG2b anti-CD8b (2.43; ATCC TIB 210); rat IgG2b anti-Fc-γII/IIIR. Biotinylated, and phycoerythrin (PE)-and FITC-conjugated mAb [anti-CD3ε (145-2C11), anti-CD4 (RM4-4), anti-CD8a (53-6.7), anti-B220 (RA3-6B2), anti-CD80 (B7-1) (1G10) and anti-Ly6G (RB6-8C5)] were obtained from PharMingen (San Diego, CA) along with the isotype-matched controls.
Flow cytofluorography and cell purification
Spleen cells from normal and cytokine-treated mice were analyzed for CD3 ϩ , CD4 ϩ , CD8 ϩ , B7 ϩ (CD80 ϩ ) and Ly6G ϩ (myeloid differentiation antigen) composition by flow cytofluorography using a FACScan (Becton Dickinson, San Jose, CA). Mice were killed with CO 2 and a single-cell suspension of nucleated cells made of each spleen. The spleen cells were treated with normal rabbit serum to block FcR binding, washed and then stained with the appropriate conjugated antibody. The stained cells were again washed and then fixed with 2% paraformaldehyde PBS solution. Throughout the staining procedure, the cells and reagents were kept at 4°C; the wash solution and the diluent used for cells and reagents was a PBS solution containing 2% FCS and 1 mM NaN 3 .
Spleen cells were sorted for Ly6G ϩ cells on a FACStar Plus (Becton Dickinson) using PE-anti-Ly6G. Spleens were made into single-cell suspensions, the erythrocytes were depleted by differential density centrifugation (Ficoll-Hypaque 1077; Sigma, St Louis, MO), and the interphase cells harvested, stained and sorted. For purposes of cell type identification, samples of sorted RB6-8C5 ϩ cell were centrifuged (Cytospin 3; Shandon) on to microscope slides, fixed and stained with Wright/Giemsa. Sorted cell samples, as well as some blood cell samples, were also tested for eosinophil content by diluting cell samples in Discombe's dilution fluid (5 volumes of 1% aqueous Eosin Y, 5 volumes of acetone and 90 volumes of distilled water) (11) .
Cytotoxicity assays
Splenic single-cell suspensions were prepared and suspended in RPMIϩ medium. Some of the cells were tested immediately for cytotoxic T lymphocyte (CTL) and NK activity as described below, and the remainder set up in microtiter plates (3524; Costar, Cambridge, MA). To each well was added 7ϫ10 6 'responder' splenic cells Ϯ 4ϫ10 5 irradiated (10 4 rad) 'stimulator' cells (e.g. P815.B7) and sufficient medium to achieve a final volume of 2 ml. On day 4 of culture, the cells (responders) were harvested, washed and resuspended in fresh medium (5ϫ10 6 cells/ml) to test for cytotoxic activity. The cytotoxicity assay whether applied immediately or at the end of 4 days of culture was as follows.
The assay was made in 96-well U-bottom microtiter plates (Falcon, Lincoln Park, NJ). Targets cells (P815.B7 or Yac) were radiolabeled for 3 h with 100 µCi [ 51 Cr]sodium chromate (Amersham, Arlington Heights, IL), washed and resuspended at 10 5 cells/ml of RPMIϩ medium. The 'responder' cells starting at 5ϫ10 6 cells/ml was serially diluted by a factor of 0.315-fold per step. Per well was added 0.1 ml of responder cells plus 0.05 ml of the target cell suspension (5000 cells). Thus, in the first well, the E:T ratio was 100:1, in the second 31.5:1, etc. Maximum 51 Cr release was determined by incubating target cells with 0.1 ml 10% Triton X-100 (Sigma) in distilled water. Spontaneous 51 Cr release was determined by incubating targets alone in medium (no responder cells). The assay plates were incubated for 4 h at 37°C in a humidified CO 2 incubator. Supernatants were harvested using a TomTec Quadra 96 (Orange, CT); radioactivity was measured using a Wallac 1450 Microbeta plus liquid scintillation counter (Turku, Finland). The results are presented as the mean of triplicate samples; the percentage of specific 51 
Results
Selection and characterization of the indicator tumor cell line
The aim of this study was to determine the role that cytokines play in the development and maintenance of an effective rejection response in vivo. The growth pattern of an immunogenic tumor was selected as the experimental read out on the assumption that the changes in tumor growth would reflect qualitative and quantitative changes induced in the rejection process.
The DBA/2 mastocytoma P815, P815.B7 and P815.NeoR cells lines were tested as potential monitors of the cytokine treatment. B6D2F1 female mice were given 10 6 tumor cell i.d. The P815.B7 tumors grew initially progressively, and between days 6 and 10, a transition from progressive to regressive growth occurred (Fig. 1) . In mice given P815.B7 cells, the mean tumor survival time (MTST) was 23 Ϯ 4 days. P815 and P815.NeoR tumors grew only progressively (Fig. 1) . None of the mice given either P815 or P815.NeoR survived. The mean survival time of the P815 or P815.NeoR inoculated mice was 22 days. To establish the immunological basis of the P815.B7 tumor destruction, scid mice were P815.B7 inoculated (10 6 tumor cell i.d.). The P815.B7 tumor grew unabated on the scid mice; the mean survival time of the scid mice (five mice) was 15 Ϯ 1 days. B6D2F1 mice were also P815.B7 inoculated, and then treated with anti-CD4 and/or anti-CD8 mAb. The results of the anti-CD4 and/or anti-CD8 treatment is summarized as follows. The tumor rejection process was compromised by antibody treatment. The timing of the regimen of injections was critical. All the mice (eight mice) treated with anti-CD4 plus anti-CD8 antibodies on days 0, 1, 6 and 7 failed to reject P815.B7. When the antibody injections were started on day 7, an effect was noted, but it was significantly weaker. Twothirds of the mice rejected the tumor; the tumor survival time in the treated mice ranged from 28 to 39 days as compared to 20 Ϯ 3 days in the controls. In a separate experiment, the antibodies were tested alone not in combination; the regimen of injections was started on day 7. The injection of anti-CD8 alone prolonged the tumor survival time; the MTST was 27 Ϯ 6 days. Injection of anti-CD4 alone had less effect; the MTST was 20 Ϯ 5 days compared to 18 Ϯ 5 days in control mice.
In all the following experiments, 2.5ϫ10 6 P815.B7 cells were injected i.d. in a 0.02 ml volume. This increase in the number of cells inoculated (10 6 to 2.5ϫ10 6 cells) did not change the growth pattern, but the size of the tumor at the peak was slightly larger (4-5 to 5-7 mm), making measurement more reproducible.
Effect of IL-4 treatment on the tumor rejection process
Recombinant IL-4 was administered as a soluble antigenantibody complex. This form of IL-4 delivery was utilized because others (10) had found that fewer injections and smaller amounts of IL-4 were required to achieve a given effect. In the following experiment, IL-4 in a IL-4 antibody complex (IL-4 CPX) was given i.p. every third day starting on day 7 and ending on day 22; 10 µg of IL-4 was given per injection. The timing of the IL-4 CPX injections and the dose of IL-4 delivered were based on results obtained in preliminary experiments. With a dose of 25 µg of IL-4 per injection and with an injection schedule that went beyond 22 days, a few deaths occurred that appeared to be due to the treatment rather than to any tumor-related pathology. Because the aim was to determine the effect of these cytokines on the effector arm of the immune response, the injection schedule was started on day 7 and terminated on day 22; if an effect were present, it was assumed that this period of treatment would be sufficient to reveal it. The dose of IL-4 delivered per injection as a CPX was also reduced to 10 µg per injection to minimize the probability of animal death seen with the higher dose.
The results obtained in control mice and in mice given IL-4 CPX are compared in Fig. 2 . results from five separate experiments distributed over a 9 month period. Five control mice were used per group. For the 25 control mice, the MTST was 22 Ϯ 3 days; the tumor initially grew progressively, peaked around day 10 and then regressed. For the IL-4 CPX-treated mice, the tumor survival time was lengthened to Ͼ30 days (Fig. 2B) ; with time, all the tumors were eventually rejected. The lengthening of the survival time was associated with the development of a 'plateau' in the growth curves, the duration of which was several days longer than the period of time the mice were under IL-4 CPX treatment. In experiments not detailed here, IL-4 CPX treatment was started on day 0 and ended on day 10; similar results were obtained in that the tumor size began to plateau in mice given IL-4 CPX injections. The length of the flatting of the tumor growth curves was not as pronounced as when the injections were started on day 7 and terminated on day 22.
To show that the lengthening of the tumor survival time was not due to IL-4 being in an immune complex, IL-4 alone was injected daily at a dose of 20 µg of per mouse. Fourteen i.p. injections were made with the first injection being on day 7 and the last one on day 20. Injections of IL-4 alone produced the same results as the injections of IL-4 CPX. Tumor survival was prolonged (Fig. 3) . Four of the five mice had tumor growth curves that 'flatten' (Fig. 3) , the duration of which roughly corresponded to the time of treatment. (Again, in results not detailed here, similar results were obtained with mice treated from day 0 to 10.) There was one tumor that appeared to be on the threshold of rejection when progressive tumor growth re-occurred. 
Effect of IL-10 treatment on the tumor rejection process
The IL-10 treatment (20 µg per injection) was started on day 7 and ended either on day 17 or 20. The tumor growth curves (Fig. 4A ) of IL-10-treated mice closely resembled that of the control mice ( Fig. 2A) . Tumor growth peaked around day 10, and the reduction in tumor size thereafter was sharp and 
Effect of IL-4 plus IL-10 treatment on the tumor rejection process
The combination of IL-10 and IL-4 treatment produced a lengthening of the tumor survival time (Fig. 4B) . Cytokine treatment was started on day 7 and ended on day 22; both IL-4 alone and IL-4 CPX were tested. The amounts of cytokines injected were as described in the above experiments. In these experiments, the 'plateau' was replaced by a rate of regression in tumor size that was slower than that observed in control mice (Fig. 2A) . This period of slowed tumor destruction corresponded roughly to the period of cytokine treatment. About day 24, the rate of tumor destruction accelerated. A slight difference in the tumor survival time was noted dependent on whether IL-4 CPX plus IL-10 (31 Ϯ 0 days) or IL-4 plus IL-10 (28 Ϯ 2 days) was used. All the tumors were rejected.
Effect of IL-4 and IL-10 on CTL activity
To determine whether the effects of these various cytokine treatments on tumor growth or rejection reflected corresponding changes in the anti-tumor immune response, spleens were taken on days 7, 14 and 21 to quantitate their capacity to generate anti-P815.B7 CTL activity following in vitro restimulation. The tumor cell inoculation and the cytokine injections were as described in the above experiments. No anti-P815.B7 cytolytic activity was observed with spleen cells without in vitro stimulation except as noted below. In control mice, recall CTL activity was readily detectable on day 7 (Fig. 5) ; it was higher on day 14 and decreased somewhat by day 21 (Fig. 6) . The recall response of mice treated with IL-10 was comparable to that of control mice at both 14 and 21 days. In contrast, mice treated with IL-4 had substantially reduced responses on day 14 and no detectable response on day 21 (Fig. 6) . Treatment with IL-4 plus IL-10 also caused significant inhibition of the recall CTL response, but the effect was intermediate between the results obtained with IL-4 alone and IL-10 alone. Relative to treatment, the patterns of tumor growth were consistent with those already described ( Figs  2-4) .
Anti-P815.B7 CTL activity by splenic cells without in vitro culture was observed only in spleens taken from IL-4-treated mice. For example, at an E:T ratio of 100:1, spleen cells from mice exposed to IL-4 lysed 14.3 Ϯ 1.7% of the P815.B7 targets and cells from IL-4 plus IL-10-treated mice lysed 9.3 Ϯ 1.2% of the target cells. These results should be compared to those obtained testing spleen cells from nontreated mice (days 7, 14 and 21) and spleen cells from IL-10-treated mice (days 14 and 21) which produced 4.7 Ϯ 0.7 and 5.2 Ϯ 1.3% lysis respectively. This cytolytic activity may reflect the enhanced NK activity in IL-4-treated mice (see below) rather than a higher level of tumor-specific CTL activity.
Effect of cytokine treatment on NK activity NK activity, as measured by the killing of YAC cells, was noted only with spleen cells from IL-4-treated mice (Fig. 7) . The level of activity did not change with time; the level of cytolytic activity measured on day 14 equaled that measured on day 21. This effect generated by IL-4 treatment was reduced by the addition of IL-10. After 4 days in culture, the anti-Yac activity disappeared; this disappearance occurred whether or not stimulator cells, i.e. irradiated P815.B7 cells, were added or not.
Pathological effects of cytokine treatment
Tumor cells were injected and cytokine treatment was as described in the above experiments; spleens were taken and weighed on day 23. IL-4 treatment led to splenomegaly, whereas IL-10 alone had no effect on spleen size ( Table 1) . The IL-4-induced splenomegaly was reduced by the addition of IL-10 ( Table 1 ). This splenomegaly was not dependent on the inoculation of P815.B7 cells nor the manner in which the IL-4 was given (soluble or complexed).
IL-4 treatment produced a marked increase in splenic granulocytes, as measured by the number of Ly6G ϩ cells (Table 2 ). In CPX-treated mice, the percentage of Ly6G ϩ cells ranged from 51 to 73%; in normal mice it was about 6%. When IL-10 was combined with IL-4 treatment, the percentage of Ly6G ϩ cells was reduced to about twice the normal value (12%). By differential staining, these Ly6G ϩ cells were predominantly neutrophils with only a small percentage (4%) of eosinophils. This increase in granulocytes produced a corresponding reduction in the percentage of splenic T and B cells. The percentage of spleen cells that were CD3 ϩ was reduced from 28 to 11%, and the percentage of spleen cells that were B220 ϩ went from 67 to 22%.
Discussion
The systemic administration of the anti-inflammatory cytokine IL-4 prolonged the survival time of P815.B7 tumors on B6D2F1 mice. The prolongation of the tumor's survival coincided with the period of cytokine treatment, i.e. with the cessation of treatment, the tumor rejection process appeared within a day or so. The impaired rejection process noted with IL-4 treatment was mirrored in vitro by the reduced capacity of spleen cells from treated mice to mount a recall CTL anti-P815.B7 response. While CD8-mediated immunity appeared to be down-regulated by IL-4 treatment, anti-Yac (NK) activity was enhanced. NK activity was observed only with fresh splenocytes, not with splenocytes re-stimulated in vitro. Treatment of mice with IL-10 alone had no measurable effect on either tumor rejection or in vitro CTL activity. In combination with IL-4, IL-10 attenuated the inhibitory effect produced by IL-4 given alone. IL-10 modulation of the IL-4 effect was noted throughout the study regardless of the parameter measured, e.g. the in vitro CTL response, NK activity or splenic size and cellular composition.
The results of earlier studies showing IL-4 enhanced tumor rejection contrast with those reported here (5) (6) (7) 12, 13) . A key difference between those studies and this one is the manner in which the cytokine was administered. In the present study the cytokine was given systemically, while in most of the earlier studies tumor cells were transfected with the IL-4 genes and the tumor cells secreted the cytokine constitutively. Thus, both the tumor and the host were exposed continuously to the cytokine from the tumor. The effects observed were primarily local and, in some cases, the effector mechanism was not T cell mediated (14) .
The effect of IL-10 on the tumor rejection process has been also tested by others (8, 15) , again using tumors transfected with cytokine genes. The results of these experiments varied significantly with the type of tumor (allogeneic versus syngeneic) and the type of IL-10 used (murine versus viral). IL-10 treatment alone appeared to have little or no effect on the anti-tumor response, although similar doses have been shown to inhibit a T h 1-mediated enterocolitis (16) and a 10-fold lower daily dose of IL-10 produced a significant therapeutic benefit in a model of T h 1-mediated autoimmunity (4) . On the other hand, IL-10 was clearly biologically active in this model as it modulated the IL-4-induced inhibitory response. In this respect, the combination of IL-4 and IL-10 treatment might have been expected to give a greater inhibition of the CTL response, analogous to the cooperative inhibitory effects observed in a delayed-type hypersensitivity (T h 1) response (17) . The mechanism for these unexpected opposing effects of IL-4 and IL-10 is not known.
Two basic immunologic effector mechanisms are considered here as primary candidates involved in the rejection of P815.B7 tumors, given that this rejection process is dependent on an intact immune system. The two effector mechanisms are cell-mediated lysis of target cells by direct cell-cell contact (CD8 CTL), and target cell killing by cytotoxic cytokines (e.g. IFN-γ, and tumor necrosis factor-α and -β) delivered in a paracrine fashion by both CD4 and CD8 T cells. In the latter case, it is conceivable that the IL-4 treatment skewed the immune response away from the production of type 1 cytokines and thus lengthened the survival of P815.B7 tumors. In experiments not detailed here, the capacity to produce IFN-γ in vitro was not abolished in spleen cells taken from IL-4-treated mice, and the rejection process was not compromised in mice treated with anti-IFN-γ antibodies. Although a mechanism based on the delivery of cytotoxic cytokines cannot be completely ruled out, its contribution to the destruction of P815.B7 tumors must be considered secondary. In contrast, the data presented here clearly demonstrate a reduction in CTL anti-P815.B7 activity in IL-4-treated mice. The precise nature of the change created by IL-4 treatment in the CTL anti-P815.B7 response remains to be determined. This reduction in CTL activity might be attributed to a reduction in the number of anti-P815.B7 cells generated and/or a reduction in their effector function. The latter possibility is suggested by the reduction in cytolytic activity which was greater than can be accounted for by the dilution of CD3 ϩ cells due to the appearance of Ly6G ϩ splenic cells in IL-4-treated mice.
The treatment of mice with either IL-4 CPX or soluble IL-4 led to a profound splenomegaly, characterized by a marked increase in the neutrophil content of the spleen and a marked increase in NK activity. This observation that NK (LAK) activity is increased following IL-4 treatment has been made by other investigators (18) (19) (20) (21) . It appears now that this enhancement of NK activity might reside in the capacity of neutrophils to synthesize and secrete IL-12 (22, 23) , a function that is incidentally augmented by IL-4 priming (24) . IL-12 is known to activate and promote the growth of NK cells (25) as well as being chemotactic for NK cells (26) .
Among the mice treated with IL-4 (CPX or soluble), the growth pattern of the tumor was to grow progressively, plateau for several days, and then regress and disappear. The fact that the tumor did not grow progressively or regress during the period of reduced CD8 ϩ CTL activity remains to be explained. That the tumors did not grow progressively might be attributed to the marked increase in NK activity in IL-4-treated mice; that the tumor did not regress might be attributed to a lower efficiency in the killing of tumor cells by NK cells than by CD8 ϩ cytolytic cells. As an alternative based on the neutrophilia associated with IL-4 treatment, it can be postulated that the reduction in tumor size was masked by the influx of neutrophils. This latter postulate does not exclude the role of NK cells but rather incorporates them, as suggested earlier.
Finally, the effect of various cytokines on the development of anti-tumor immunity has been studied by many investigators to assess the therapeutic potential of these molecules (7) . Most of these animal models use transplantable tumors that are either poorly immunogenic or grow too rapidly to be effectively controlled by an immune response, or both. Such studies form the preclinical rationale for many current and planned clinical trials of anti-tumor therapy with cytokines. There is concern, however, that these studies do not adequately evaluate inhibitory effects these cytokines may have on normal anti-tumor responses that restrain tumor progression in patients with primary tumors. Using an aggressive tumor line that has been genetically modified to render it controllable by a combination of CD4 ϩ and CD8 ϩ T cells, we show that, for IL-4, the immunosuppressive effects can outweigh possible anti-tumor activities of the cytokine. Our results also show that high systemic doses of IL-10 may not have the inhibitory effects on anti-tumor CTL responses observed with some IL-10-transfected tumors and can modulate the net inhibitory effects of IL-4. We suggest that a complete view of the therapeutic potential of any immunomodulatory cytokine should include assessments of its effects in models that show significant immunological control of tumor growth. 
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